title: Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With Influenza Infection: An Asian Population Cohort Study.
abstract: There are limited population-based studies on the progress of oseltamivir therapy for influenza infection.Using insurance claims data of 2005, 2009, and 2010, the authors established an "in-time" cohort and a "lag-time" cohort representing influenza patients taking the medicine within and not within 1 week to examine the treatment progress. Incident outpatient visit, emergency care and hospitalization, and fatality were compared between the 2 cohorts in the first week and the second week of follow-up periods, after the oseltamivir therapy.A total of 112,492 subjects diagnosed with influenza on oseltamivir therapy in 2005, 2009, and 2010 were identified. The multivariate logistic regression analysis showed that the in-time treatment was superior to the lag-time treatment with less repeat outpatient visits, hospitalizations, and fatality. The overall corresponding in-time treatment to lag-time treatment odds ratios (OR) were 0.50, 0.54, and 0.71 (all P value < 0.05), respectively. The in-time to lag-time ORs of all events were 0.50 in 2009 and 0.54 in 2010.Our study demonstrates that the in-time oseltamivir therapy leads to significantly better treatment outcomes. Oseltamivir should be administered as early as the onset of influenza symptoms appears.
authors.affiliation: From the Department of Public Health, China Medical University, Taichung (C-BW, M-LC, P-CL, W-ML, C-YC, Y-JC, T-NW, F-CS); Institute of Population Health Sciences, National Health Research Institutes, Zhunan (M-LC); Department of Internal Medicine, Division of Infectious Diseases, China Medical University Hospital (P-CL, J-HW); Graduate Institute of Biostatistics, Biostatistics Center, China Medical University, Taichung (W-ML); Epidemiology and Biostatistics Center, Changhua Christian Hospital, Changhua (Y-JC); Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan (F-CS).
authors.forename: Chang-Bi
authors.initials: CB
authors.lastname: Wang
authors.forename: Mu-Lin
authors.initials: ML
authors.lastname: Chiu
authors.forename: Po-Chang
authors.initials: PC
authors.lastname: Lin
authors.forename: Wen-Miin
authors.initials: WM
authors.lastname: Liang
authors.forename: Chiu-Ying
authors.initials: CY
authors.lastname: Chen
authors.forename: Yu-Jun
authors.initials: YJ
authors.lastname: Chang
authors.forename: Trong-Neng
authors.initials: TN
authors.lastname: Wu
authors.forename: Jen-Hsien
authors.initials: JH
authors.lastname: Wang
authors.forename: Fung-Chang
authors.initials: FC
authors.lastname: Sung
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D044466:Asian People; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000208:ethnology / Q000401:mortality*; D007297:Inpatients / Q000706:statistics & numerical data; D007345:Insurance Claim Review; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000008:administration & dosage / Q000627:therapeutic use*; D010045:Outpatients / Q000706:statistics & numerical data; D012189:Retrospective Studies; D017678:Sex Distribution; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D053139:Oseltamivir